Drug-induced skin, nail and hair disorders

Drug Safety

Volumn 30, Issue 11, 2007, Pages 1011-1030

  Valeyrie Allanore, Laurence ^a,b   Sassolas, Bruno ^c,d   Roujeau, Jean Claude ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d CHU MORVAN   (France)

Author keywords

Adverse drug reactions; Hair disorders, drug induced; Nail disorders, drug induced; Skin disorders, drug induced

Indexed keywords

ADRENALIN; ALLOPURINOL; AMINOPENICILLIN; AMIODARONE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPRURITIC AGENT; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METHOTREXATE; MUSCLE RELAXANT AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENOTHIAZINE; PHOTOSENSITIZING AGENT; PSORALEN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SULFONAMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VORICONAZOLE;

ACNE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DISEASE SEVERITY; DRUG ERUPTION; DRUG INDUCED DISEASE; FIXED DRUG ERUPTION; GRANULOMA; HAIR COLOR; HAIR LOSS; HIRSUTISM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTRICHOSIS; LUPUS LIKE SYNDROME; NAIL COLOR DEFECT; NAIL DISEASE; ONYCHOLYSIS; ONYCHOMADESIS; PARONYCHIA; PATHOPHYSIOLOGY; PEMPHIGUS; PHOTOALLERGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PSEUDOLYMPHOMA; PSEUDOPORPHYRIA; PUSTULOSIS; REVIEW; SERUM SICKNESS; SKIN NECROSIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

EID: 35648946929     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730110-00003     Document Type: Review

References (70)

1. Lazarou J, Pomeranz BH, Covey PN. Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Arndt KA, Jick H. Rates of cutaneous reactions to drug: a report from the Boston Collaborative Drug Surveillance Program. JAMA 1976; 235: 918-23
3. Hunziker T, Künzi U, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93
4. Caranasos GJ, May FE, Stewart RB, et al. Drug-associated deaths of medical inpatients. Arch Intern Med 1976; 136: 872-5
5. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-91
6. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93
7. Roujeau J-C, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994; 331: 1272-85
8. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquired Immune Defic Syndrome 1992; 5: 1237-57
9. Floret D. Clinical aspects of streptococcal and staphylococcal toxinic diseases. Arch Pediatr 2001; 8 Suppl. 4: 762S-8S
10. Gruchalla RS, Pirmohamed M. Clinical practice: antibiotic allergy. N Engl J Med 2006; 354: 601-9
11. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9
12. Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol 2006; 30: 19-23
13. Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134: 1575-80
14. Hedner T, Samuelsson O, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304: 941-6
15. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25: 345-72
16. Crowson AN, Mihm Jr MC, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003; 30: 161-73
17. Jorg I, Fenyvesi T, Harenberg J. Anticoagulant-related skin reactions. Expert Opin Drug Saf 2002; 1: 287-94
18. Beylot C, Bioulac P, Doutre MS. Acute generalized exanthematic pustuloses (four cases) [in French]. Ann Dermatol Venereol 1980; 107: 37-48
19. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-9
20. Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433-41
21. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333-8
22. Knowles SR, Shapiro LE, Shear NH. Anticonvulsivant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21: 489-501
23. Callot V, Roujeau J-C, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996; 132: 1315-21
24. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 1826-32
25. Maguire JH, Wettrell G, Rane A. Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy. Br J Clin Pharmacol 1987; 24: 554-7
26. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug induced hypersensitivity syndrome. Br J Dermatol 1998; 139: 1026-32
27. Descamps V, Valance A, Edlinger C, et al. Association of herpesvirus 6 infection in drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-4
28. Begon E, Roujeau JC. Drug reaction with eosinophilia and systemic symptoms. Ann Dermatol Venereol 2004; 131: 293-7
29. Kauppinen K, Stubb S. Fixed eruptions: causative drugs and challenge tests. Br J Dermatol 1985; 112: 575-8
30. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992): structure and results of a population based registry. J Clin Epidemiol 1996; 49: 769-73
31. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002; 14: 143-50
32. Saïag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-74
33. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocytes death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-4
34. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3
35. Wolkenstein P, Latarget J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9
36. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulphonamides and anticonvulsants. Arch Dermatol 1995; 131: 544-51
37. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens Johnson syndrome. Nature 2004; 428: 486
38. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005; 102: 4134-9
39. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-6
40. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. SCAR Study Group. Arch Dermatol 2002; 138: 1019-24
41. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53
42. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-6
43. Rabelink NM, Brakman M, Maartense E, et al. Erythema multiforme vs Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction. Ned Tijdschr Geneeskd 2003; 147: 2089-94
44. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-9
45. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6
46. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7
47. Wintroub BU, Stern R. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167-79
48. Susser WS, Whitaker-Worth DL, Grant Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367-98
49. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16: 393-7
50. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-12
51. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control-study. Arch Dermatol 1996; 132: 272-6
52. Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157-66
53. Souteyrand P, d'Incan M, Parent S. Misleading of rare cutaneous drug reactions. Rev Prat 2000; 50: 1329-33
54. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
55. Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol 1995; 34: 149-58
56. Tosi A, Misciali C, Piraccini BM, et al. Drug-induced hair loss and hair growth: incidence, management and avoidance. Drug Saf 1994; 10: 310-7
57. Faivre S, Delbado C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35
58. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-6
59. Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 2002; 46: 284-93
60. Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21: 187-201
61. Hussain S, Anderson DN, Salvatti ME, et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000; 88: 2367-71
62. Chen GY, Chen YH, Hsu MM, et al. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001; 145: 521-2
63. Mehra A, Murphy RJ, Wilson BB. Idiopathic familial onychomadesis. J Am Acad Dermatol 2000; 43: 349-50
64. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984; 4: 677-8
65. Tosti A, Pirraccini BM, D'Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140: 1165-8
66. Chang GC, Yang TY, Chen KC, et al. Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22 (22): 4646-8
67. Boucher KW, Davidson K, Mirakhur B, et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 47: 632-3
68. Rahav G, Maayan S. Nail pigmentation associated with zidovudine: a review and report of a case. Scan J Infect Dis 1992; 24: 557-61
69. Angeloni VL, Salasche SJ, Oriz R. Nail, skin and scleral pigmentation induced by minocycline. Cutis 1987; 40: 229-33
70. Dixit VB, Chaudhary SD, Jain VK. Clofazimine-induced nail changes. Indian J Lepr 1989; 61: 476-8